Leading Paediatric Oncologist Dr. Noah Federman Joins Zelda Therapeutics Scientific Advisory Board. Dr. Federman joins an established and well credentialed Scientific Advisory Board and follows the recent appointment of leading clinician Dr. Joe Goldstrich. His appointment follows the recent appointment of leading US clinician Dr. Joe Goldstrich, in February 2016 and signals the strong level of medical and scientific support for Zelda s strategy to validate the efficacy of medical cannabis in key indications.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.48 AUD | -4.00% | -2.04% | -46.67% |
05-23 | Zelira Therapeutics Receives Third-Tranche of Funding for HOPE Clinical Trials | MT |
04-15 | Zelira Therapeutics Receives AU$919,000 Funding Under Australian Government’s R&D Tax Incentive Scheme | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-46.67% | 3.76M | |
+12.30% | 116B | |
+12.15% | 106B | |
-8.14% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.33% | 16.33B | |
+5.80% | 14.14B | |
+28.03% | 12.02B |
- Stock Market
- Equities
- ZLD Stock
- News Zelira Therapeutics Limited
- Zelda Therapeutics Pty Ltd Appoints Noah Federman to the Scientific Advisory Board